Home › Research › Health systems and care delivery
High-Cost Cancer Drug Use in Medicare Advantage and Traditional Medicare
Cathy J. Bradley, Rifei Liang, Richard C. Lindrooth, Lindsay M. Sabik, Marcelo C. Perraillon. JAMA Health Forum, 2025-01-10
Topic: Risk, prevention and care in population studies
Plain-language summary
Results Of 4240 patients included in the analysis (mean [SD] age, 75 [7] years; 2327 [54.9%] female), 1991 were diagnosed with CRC and 2249 with NSCLC. Nonetheless, MA was modestly associated with reduced high-cost drug utilization and may reduce overall treatment costs.
What this study adds
Evidence grade: Moderate
This is a follow-up (cohort) study of 4,240 participants. This study examined use of high-cost cancer drugs among Medicare beneficiaries with colorectal or lung cancer. Reported effect size: 54.9%.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Bradley, C. J., Liang, R., Lindrooth, R. C., Sabik, L. M., & Perraillon, M. C. (2025). High-Cost Cancer Drug Use in Medicare Advantage and Traditional Medicare. JAMA Health Forum. https://doi.org/10.1001/jamahealthforum.2024.4868
Vancouver
Bradley CJ, Liang R, Lindrooth RC, Sabik LM, Perraillon MC. High-Cost Cancer Drug Use in Medicare Advantage and Traditional Medicare. JAMA Health Forum. 2025. doi:10.1001/jamahealthforum.2024.4868.
BibTeX
@article{bradley2025-293e0750,
author = {Bradley, Cathy J. and Liang, Rifei and Lindrooth, Richard C. and Sabik, Lindsay M. and Perraillon, Marcelo C.},
title = {{High-Cost Cancer Drug Use in Medicare Advantage and Traditional Medicare}},
journal = {JAMA Health Forum},
year = {2025},
doi = {10.1001/jamahealthforum.2024.4868},
url = {https://doi.org/10.1001/jamahealthforum.2024.4868}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Results Of 4240 patients included in the analysis (mean [SD] age, 75 [7] years; 2327 [54.9%] female), 1991 were diagnosed with CRC and 2249 with NSCLC.
- Nonetheless, MA was modestly associated with reduced high-cost drug utilization and may reduce overall treatment costs.
Why it matters
This study examined use of high-cost cancer drugs among Medicare beneficiaries with colorectal or lung cancer. It provides no information on treating, curing or preventing Alzheimer's disease.
Study details
- Study designcohort study
- Participants4,240
- Effect size54.9%
- Evidence strengthModerate
How this study scored 53/100
Published in a peer-reviewed journal, and it is a cohort study following people over time. Scored zero for randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (JAMA Health Forum) |
| Journal's citation record | 0 / 4 | JAMA Health Forum: journal h-index 60 (OpenAlex, 2026-10-29) |
| Study design | 7 / 12 | A cohort study following people over time |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 3 / 4 | 4,240 participants |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 2 / 7 | Cited 11 times (OpenAlex, 2026-10-10) |
| Citations per year | 2 / 5 | 3.7 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 4 / 6 | Cited 10.7× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 1 / 4 | Cited 11 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Marcelo Coca Perraillon: h-index 22 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | University of Pittsburgh: institution h-index 1,470 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 3 institution(s) in 1 country |
| Indexed in PubMed | 1 / 2 | Not in PubMed, but has a DOI |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 53 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Health systems and care delivery from nearby years
Also in Health systems and care delivery
172 studies in the library are filed under Health systems and care delivery with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Health systems and care delivery hub.